Stereoselective halofantrine disposition and effect: Concentration-related QTc prolongation

British Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2001, Pages 231-237

  Abernethy, Darrell R ^a,b   Wesche, David L ^a,b   Barbey, Jean T ^a,b   Ohrt, Colin ^a,b   Mohanty, Sarina ^a,b   Pezzullo, John C ^a,b   Schuster, Brian G ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Halofantrine; QTc; Stereoselective clearance

Indexed keywords

HALOFANTRINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STEREOCHEMISTRY;

ADULT; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METABOLIC CLEARANCE RATE; MOLECULAR CONFORMATION; PHENANTHRENES;

EID: 0035033450     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.00351.x     Document Type: Article

References (32)

1. Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171, 669)
2. Malaria: Treatment efficacy of halofantrine (WR 171, 669) in initial field trials in Thailand
3. Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand
4. Pharmacokinetics of halofantrine in healthy Thai volunteers
5. Pharmacokinetics of halofantrine in man: Effects of food and dose size
6. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers
7. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria
8. Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria
9. A physicochemical basis for the effect of food on the absolute bioavailability of halofantrine
10. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state
11. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients
12. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologus enzyme expression systems
13. Halofantrine: A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential
14. Cardiac effects of antimalarial treatment with halofantrine
15. Prolonged QT interval with halofantrine
16. Prolonged QT interval with halofantrine
17. Cardiac effect of halofantrine
18. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome
19. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria
20. Cardiac effects of standard-dose halofantrine therapy
21. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation
22. Mechanism of cardiotoxicity of halofantrine
23. X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity
24. The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high performance liquid chromatography
25. The electrocardiographic effects of cetirizine in normal subjects
26. QT interval: A measure of drug action
27. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken
28. An analysis of the time relations of electrocardiograms
29. The measurement of the Q-T interval of the electrocardiogram
30. Prolonged accumulation of diazepam in obesity
31. An algorithm for least-squares estimation of non-linear parameters
32. Pharmacokinetic and pharmacodynamic modeling in vivo